Endocrine Abstracts

Key4OI : Development and implementation of a Standard set of Outcome measures for Osteogenesis Imperfecta. Osteogenesis Imperfecta (OI) is a genetic disorder also known as ‘brittle bone disease’. The clinical manifestation of OI shows a wide variation. Therefore, care for patients with OI requires an interdisciplinary approach. The effectiveness of particular interventions and treatment protocols of interdisciplinary teams is not clear due to a non-standardized and w...

In 2015 AdrenalNET organized a roundtable conference with patient representatives, prescribers and pharmaceutical industry. The cause of this meeting was complaints of patients about the problematic hydrocortisone market in the Netherlands, characterized by frequent availability issues (shortage ) of the hydrocortison tablets/capsules and frequent changes in manufacturers (compounding companies) leading to quality issues. All parties at the roundtable meeting agreed to join fo...

Background: Osteogenesis Imperfecta (OI) is commonly defined as ‘brittle bones’ disease, but there are also more characteristics like blue sclerae, hearing loss, dental problems, ligamentous laxity and a short stature. Easy bruising is also a very common feature and there are multiple case reports on haemorrhagic events in OI. Larger population studies on bleeding tendency in OI are very sparse, while other connective tissue disorders with easy bruising have much mor...

Objective: Growth hormone treatment (GHT) is a widely accepted treatment in growth hormone deficient (GHD) adults with nonfunctioning pituitary adenoma (NFPAs). However, concerns remain about the safety of GHT, because of its potentially stimulating effect on tumour (re)growth. The aim of this study was to evaluate tumour progression in NFPA patients using GHT.Patients and methods: From the Dutch National Registry of growth hormone treatment in adults, a...

Background: Hypopituitarism after traumatic brain injury (TBI) is considered to be a prevalent condition, and may affect quality of life (QoL) and cognitive function. However, the prevalence of hypopituitarism differs considerably among reported studies due to differences in definitions, endocrine assessments of hypopituitarism, and confounding factors, like timing of evaluation and the severity of the trauma.Aim: To evaluate the prevalence of hypopituit...